How to Value a Urology Practice in 2026

Urology is one of the hottest specialties in healthcare M&A right now, and for good reason. The combination of an aging male population, high-margin in-office procedures, and significant ancillary revenue streams makes urology practices extremely attractive to private equity. I've watched multiples climb steadily over the last five years, and practices that would have sold for 5-6x EBITDA in 2020 are now commanding 7-10x in the right circumstances.

But not every urology practice is created equal. A two-physician general urology group doing mostly clinic visits is a fundamentally different asset than an eight-provider practice with in-office IMRT, a lithotripsy suite, and a pathology lab. Understanding what drives that valuation gap is critical whether you're buying or selling.

The Two-Tier Market: Private Sales vs. PE Platforms

Like dental practices, urology has bifurcated into two distinct buyer pools with different valuation frameworks.

Private physician buyers — another urologist or a small group looking to expand — typically value practices at 5-7x EBITDAor a percentage of collections (50-70%). They're buying a job with upside, and they underwrite based on what the practice can support after debt service and their own compensation. These buyers are increasingly rare for larger practices because few individual physicians can fund a $3M+ acquisition.

PE-backed platforms — Solaris Health, US Urology Partners, Urology Management Associates, and others — are the dominant buyers in 2026. They're paying 7-10x EBITDA for platform-quality groups and 5-7x for bolt-on acquisitions. The premium reflects their access to cheap capital, their ability to extract synergies across a multi-site network, and the strategic value of controlling referral patterns in a market.

The math is straightforward: a 6-provider practice generating $2.5M in EBITDA might sell for $12.5M to a private buyer (5x) or $20-25M to a PE platform (8-10x). That's not a rounding error — it's a life-changing difference for the selling physicians.

Ancillary Revenue Is Where the Value Lives

The single biggest driver of urology practice valuation is the percentage of revenue generated from ancillary services versus clinic E&M visits. Office visits are necessary but low-margin. Ancillary services are where urology practices generate the cash flow that justifies premium multiples.

In-office procedures. Cystoscopies, prostate biopsies, vasectomies, urodynamics testing, and Rezum/UroLift procedures performed in the office rather than the hospital generate dramatically higher margins. The equipment investment is significant ($200K-$500K for a fully equipped procedure room), but the per-procedure margin dwarfs what you earn on a clinic visit. Buyers specifically model what percentage of procedures are done in-office versus referred to a hospital ASC.

Radiation therapy (IMRT/SBRT). This is the crown jewel of urology ancillary revenue. A practice with an in-office linear accelerator providing intensity-modulated radiation therapy for prostate cancer can generate $1-3M in additional annual revenue per machine. The capital investment is $3-5M, but the payback period is typically 18-30 months. Practices with established radiation programs are valued at the absolute top of the range.

Lithotripsy. Extracorporeal shockwave lithotripsy (ESWL) for kidney stones — whether through a mobile unit partnership or an owned unit — adds a high-margin revenue stream. Ownership of the lithotripsy unit versus a management agreement with a mobile service matters significantly for valuation purposes.

Pathology and lab services. In-house pathology reading, especially for prostate biopsies with Gleason scoring, generates excellent margins and reduces turnaround time for patients. Practices that have brought pathology in-house (either through employment of a pathologist or a joint venture) capture the technical and professional components that would otherwise go to an outside lab.

Provider Count and Composition

PE buyers have a strong preference for practices with 4+ urologists. Below that threshold, the practice is too dependent on individual providers and too small to serve as a platform. Solo and two-physician practices can still sell, but they'll be bolt-on acquisitions at lower multiples.

The composition of your provider team matters as much as the headcount. Buyers evaluate:

• Age distribution: A practice where four of five urologists are over 60 has significant succession risk. Buyers want to see a mix of senior and mid-career physicians who will stay post-acquisition.
• Sub-specialization: Urologic oncology, female pelvic medicine, pediatric urology, and male infertility specialists add breadth that attracts more referrals and supports higher revenue per provider.
• APP leverage: Practices that effectively use nurse practitioners and physician assistants for follow-up visits, post-op checks, and basic consults demonstrate operational efficiency. A ratio of 1 APP per 2-3 urologists is common in well-run groups.

Retention agreements matter enormously. If the selling physicians plan to retire within 12-24 months of closing, the buyer is essentially paying for a patient panel and referral relationships without the providers who drive them. Most PE deals require physicians to sign 3-5 year employment agreements, and the multiple offered often correlates directly with the commitment length.

The PE Consolidation Wave in Urology

Urology is roughly where dermatology was in 2018 — early-to-mid innings of a PE rollup cycle. Multiple platform companies are actively acquiring, competition for quality practices is intense, and multiples are at or near their cyclical peak.

What does this mean for sellers? Timing matters. The window of peak multiples in any specialty consolidation cycle typically lasts 3-5 years before the market saturates and platforms shift from growth-at-any-price to margin optimization. We're likely in years 3-4 of that window for urology.

For practices considering a PE partnership, the structure typically involves selling 60-80% of the practice at closing, retaining 20-40% equity that rolls into the platform, and participating in a "second bite of the apple" when the platform eventually recapitalizes (usually 4-6 years later). The retained equity often generates returns of 2-4x, meaning the total economic outcome can significantly exceed the headline multiple.

What Depresses Urology Practice Value

Hospital-dependent surgery. If all your surgical cases go to the hospital and you have no ASC ownership or in-office procedure capability, you're leaving the highest-margin revenue on the table. Buyers will model the cost of building out in-office capabilities post-acquisition and discount accordingly.

Payer mix tilted to Medicare. Urology skews older, so Medicare is always a significant payer. But practices where Medicare exceeds 60% of revenue face reimbursement risk that buyers price in. Diversification toward commercial payers and Medicare Advantage plans provides some buffer.

No EMR or outdated systems. Practices still on paper charts or running a 2010-era EMR signal operational neglect. Buyers will budget $200-400K for a system migration and deduct it from their offer.

Lease concentration risk. If your main office lease expires within two years and you don't have favorable renewal terms, buyers see location risk. Secure long-term leases with reasonable escalation clauses before going to market.

Maximizing Your Urology Practice Value

The highest-impact moves for a urology practice planning to sell in 2-3 years:

Bring procedures in-house. Every cystoscopy, biopsy, and urodynamics study performed in your office instead of a hospital facility is pure margin. If you don't have a procedure room, build one. The capital cost pays for itself within the first year and permanently elevates your valuation.

Evaluate radiation therapy. If your practice manages 50+ prostate cancer patients annually, an in-office IMRT program may be the single most valuable investment you can make. The revenue impact is measured in millions, and practices with established radiation programs command the highest multiples in the specialty.

Recruit younger physicians. Adding a mid-career urologist or a fellowship-trained sub-specialist reduces succession risk and demonstrates growth capacity. PE buyers are building for the next decade — they need providers who will be practicing through their hold period.

Talk to multiple platforms. Run a competitive process. With 5+ active PE-backed urology platforms in the market, you should have multiple parties at the table. I've seen competitive processes add 1-2 full turns of EBITDA to the winning bid.

The Bottom Line

Urology practice valuation in 2026 is driven by ancillary revenue, provider depth, and timing within the PE consolidation cycle. Practices with in-office procedures, radiation therapy, and 4+ urologists are commanding 7-10x EBITDA from aggressive platform buyers. The window is open, but it won't stay open forever. If you're a urology group considering a transaction, now is the time to maximize your ancillary capabilities and engage the market while competition among buyers is still fierce.